How it works
From Analysis to Strategy
Red Sparrow International is designed to offer a unique approach beyond traditional consulting firms
The objective is to provide management and boards with experienced, independent strategic judgment.
For a European biotech company, that may mean determining whether it is ready to approach U.S. investors—or whether additional work is needed first.
It may mean identifying the pharmaceutical companies most likely to have a strategic interest in a particular technology.
It may mean evaluating whether an asset should be financed independently, licensed, partnered or positioned for a larger strategic transaction.
Or it may simply mean providing management with an experienced U.S. perspective before entering an important conversation.
The goal is better decisions, better positioning and better access to opportunity.
The Red Sparrow Difference
Scientific Understanding
Deep familiarity with biotechnology, drug development, scientific innovation and the competitive landscape.
Investment Experience
Years of experience evaluating biotechnology companies from the perspective of professional investors.
Strategic Judgement
The ability to translate complex scientific and financial information into practical strategic alternatives.
Wall Street Perspective
An understanding of how U.S. public-market investors analyze biotechnology companies, catalysts, risk and valuation.
International Perspective
An understanding of how U.S. public-market investors analyze biotechnology companies, catalysts, risk and valuation.
Hedge Fund Experience
Direct experience making investment decisions in an environment where capital allocation, timing and risk management are critical.
An experienced biotechnology & investment professional
Steven P. Delco
Steven Delco brings decades of experience at the intersection of biotechnology, financial markets, investment management and strategic analysis.
His career has given him a perspective that is unusual within the biotechnology industry: he has evaluated biotechnology companies from the standpoint of a scientist, analyzed them as a Wall Street professional, invested in them as a portfolio manager, and communicated their opportunities and risks to sophisticated investors.
That experience provides a valuable perspective for European biotechnology companies seeking to enter the U.S. capital and strategic markets.
Understanding Both Sides of the Table
A biotechnology CEO preparing to meet a U.S. investor or pharmaceutical company is often dealing with sophisticated counterparties who will evaluate the company from multiple perspectives simultaneously.
They will ask:
- Is the science real?
- Is the technology differentiated?
- What is the probability of success?
- How large is the commercial opportunity?
- What are the competitive threats?
- What milestones could change the valuation?
- How much capital will be required?
- What strategic alternatives exist?
- Why should we invest or partner now?
Steven’s background allows him to approach these questions from the perspective of someone who has spent decades asking them himself. That is the foundation of Red Sparrow International’s advisory approach.
Building Connections that can Create Value
European biotechnology has exceptional scientific talent and increasingly sophisticated companies.
redsparrowint 